STOCKHOLM, May 19, 2020 /PRNewswire/ -- IRRAS AB (publ)
("IRRAS", or the "Company") announces that Nasdaq Stockholm's
listing committee has approved the Company for listing on Nasdaq
Stockholm's main list. In connection with the list change from
Nasdaq First North Premier Growth Market to Nasdaq Stockholm's main
list the Company has prepared a prospectus that has been approved
and registered by the Swedish Financial Supervisory Authority. The
prospectus is available on IRRAS' website, www.irras.com,
and will be available on SFSA's website,
www.fi.se.
The first day of trading on Nasdaq Stockholm's main market is
20 May 2020. The last day of trading
on Nasdaq First North Premier Growth Market is 19 May 2020.
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring
product lines to hospitals worldwide through its direct sales
organization in the United States
and select European countries as well as an international network
of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier Growth
Market (ticker: IRRAS). Redeye AB is certified adviser of the
company with email, certifiedadviser@redeye.se, or phone +46-8-121
-576-90.
For more information, please contact:
USA
Kleanthis G. Xanthopoulos,
Ph.D.
President and CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46-73-951-95-02
sabina.berlin@irras.com
The information was sent for publication, through the agency
of the contact person set out above, on 19
May 2020, at 17:00 CET.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-has-been-approved-for-listing-on-nasdaq-stockholm-and-publishes-prospectus,c3116136
The following files are available for download:
https://mb.cision.com/Main/16550/3116136/1250669.pdf
|
IRRAS has been
approved for listing on Nasdaq Stockholm and publishes
prospectus
|
View original
content:http://www.prnewswire.com/news-releases/irras-has-been-approved-for-listing-on-nasdaq-stockholm-and-publishes-prospectus-301061865.html
SOURCE IRRAS